PPG Industries, Inc. vs 10X Genomics Inc — how do they compare? PPG Industries, Inc. trades at $105.43 (market cap $23.44B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: PPG Industries, Inc. is far larger — about 2.3× 10X Genomics Inc's market cap, and PPG Industries, Inc. pays a 2.81% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and 10X Genomics Inc for 92 Days on average.
| PPG | TXG | |
|---|---|---|
Market Cap | $23.44B | $10.07B |
Volume | 2,064,777 | 5,657,286 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $97.74 |
52-Week Low | $94.34 | $11.48 |
Typical Hold Time | 68 Days | 92 Days |
Enterprise Value | $29.31B | $9.59B |
Dividend Yield | 2.81% | — |
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $105.08, down 1.37% on the day, with technical indicators showing bearish momentum. The stock demonstrates solid fundamentals with a P/E of 15.08, net income margin of 9.57%, and strong cash flow generation of $1.94B from operations in 2025. Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing estimates, while the company maintains its Dividend King status with consistent payouts.
The outlook remains cautiously optimistic with a $130 consensus price target representing 24% upside potential. Key risks include margin pressures in the Automotive Refinish segment and European demand weakness. Analyst consensus leans bullish with 55% buy ratings, though technical weakness suggests potential near-term consolidation before fundamental strength drives recovery.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →